<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39364548</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2059-2310</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>HLA</Title><ISOAbbreviation>HLA</ISOAbbreviation></Journal><ArticleTitle>Analysis of KIR and HLA Polymorphism in Chinese Individuals With COVID-19.</ArticleTitle><Pagination><StartPage>e15715</StartPage><MedlinePgn>e15715</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/tan.15715</ELocationID><Abstract><AbstractText>Killer-cell immunoglobulin-like receptor (KIR) interactions with HLA class I have crucial roles in modulating NK cell function in response to viral infections. To explore the correlation between KIR/HLA and susceptibility to SARS-CoV-2 infection, we analysed polymorphism of KIR genes, haplotypes, HLA allotypes, and the interplay between KIR and HLA in individuals diagnosed with COVID-19. Compared to a population control group, we observed a significantly increased frequency of KIR3DL3*00802 in the COVID-19 group. When encoded by the HLA-B gene, the frequency of HLA-Bw4, a ligand for KIR3DL1, was at lower frequency in the COVID-19 group. Additionally, significantly elevated frequencies of KIR-Bx3, KIR3DL3*00301, 3DL3*048, and C1<sup>+</sup>HLA-C were identified in the COVID-19 group before multiple test correction, suggesting associations with susceptibility to SARS-CoV-2 infection. Our findings indicate that the KIR3DL3*00802 allele may be a high-risk factor for SARS-CoV-2 infection, while Bw4 encoded by HLA-B gene may confer protective effects against the infection.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Sudan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3865-2250</Identifier><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norman</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kichula</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Lina</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6791-7871</Identifier><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Nanying</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Faming</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1963-9176</Identifier><AffiliationInfo><Affiliation>Institute of Transfusion Medicine, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LGF22H080004</GrantID><Agency>Zhejiang Provincial Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>R01 AI158410</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2022KY139</GrantID><Agency>Science Research Foundation of Zhejiang Healthy Bureau</Agency><Country /></Grant><Grant><GrantID>R01 AI158410</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2024KY941</GrantID><Agency>Science Research Foundation of Zhejiang Healthy Bureau</Agency><Country /></Grant><Grant><GrantID>82200258</GrantID><Agency>National Science Foundation of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>HLA</MedlineTA><NlmUniqueID>101675570</NlmUniqueID><ISSNLinking>2059-2302</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015235">HLA-B Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C042388">HLA-Bw4 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C515109">KIR3DL3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054340">Receptors, KIR</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="Y">HLA Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015235" MajorTopicYN="N">HLA-B Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054340" MajorTopicYN="Y">Receptors, KIR</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">KIR</Keyword><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">KIR/HLA interaction</Keyword><Keyword MajorTopicYN="N">NK cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364548</ArticleId><ArticleId IdType="mid">NIHMS2026016</ArticleId><ArticleId IdType="pmc">PMC11458138</ArticleId><ArticleId IdType="doi">10.1111/tan.15715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pareek M, Bangash MN, Pareek N, Pan D, Sze S, Minhas JS, et al. Khunti, Ethnicity and COVID-19: an urgent public health research priority. Lancet (2020) 395: 1421–2. doi: 10.1016/S0140-6736(20)30922-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30922-3</ArticleId><ArticleId IdType="pmc">PMC7173801</ArticleId><ArticleId IdType="pubmed">32330427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol (2021) 19: 141–54. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother (2021) 17: 62–83. doi: 10.1080/21645515.2020.1797369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1797369</ArticleId><ArticleId IdType="pmc">PMC7872062</ArticleId><ArticleId IdType="pubmed">32783700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol (2022) 94: 1641–9. doi: 10.1002/jmv.27526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27526</ArticleId><ArticleId IdType="pubmed">34914115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect (2022) 11: 277–83. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol (2022) 22: 112–23. doi: 10.1038/s41577-021-00558-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00558-3</ArticleId><ArticleId IdType="pmc">PMC8194386</ArticleId><ArticleId IdType="pubmed">34117484</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard NF, Alsulami K, Pavey E, Dupuy FP. NK Cells in Protection from HIV Infection. Viruses (2022) 14: 1143. doi: 10.3390/v14061143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061143</ArticleId><ArticleId IdType="pmc">PMC9231282</ArticleId><ArticleId IdType="pubmed">35746615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X, Bi J. Prospects for NK-based immunotherapy of chronic HBV infection. Front Immunol (2022) 13: 1084109. doi: 10.3389/fimmu.2022.1084109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1084109</ArticleId><ArticleId IdType="pmc">PMC9797727</ArticleId><ArticleId IdType="pubmed">36591230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashirova AA, Thomas R, Carrington M. HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol (2011) 29:295–317. doi: 10.1146/annurev-immunol-031210-101332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101332</ArticleId><ArticleId IdType="pmc">PMC3725604</ArticleId><ArticleId IdType="pubmed">21219175</ArticleId></ArticleIdList></Reference><Reference><Citation>Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol (2013)13:133–44. doi: 10.1038/nri3370. Epub 2013 Jan 21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3370</ArticleId><ArticleId IdType="pmc">PMC3956658</ArticleId><ArticleId IdType="pubmed">23334245</ArticleId></ArticleIdList></Reference><Reference><Citation>Manser R, Weinhold S, Uhrberg M. Human KIR repertoires Shaped by genetic diversity and evolution. Immunol Rev (2015) 267: 178–96. doi: 10.1111/imr.12316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12316</ArticleId><ArticleId IdType="pubmed">26284478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson TJ, Jobim M, Jobim LF, Portela P, Salim PH, Rosito MA, et al. Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn’s disease and ulcerative colitis. Hum Immunol (2010) 71:293–7. doi: 10.1016/j.humimm.2009.12.006. Epub 2010 Jan 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2009.12.006</ArticleId><ArticleId IdType="pubmed">20036705</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B. Human Diversity in Killer Cell inhibitory receptor genes. Immunity (1997) 7: 753–63. doi: 10.1016/s1074-7613(00)80394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1074-7613(00)80394-5</ArticleId><ArticleId IdType="pubmed">9430221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock NR, Harrison GF, Norman PJ. Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health. J Allergy Clin Immunol Pract (2022) 10:1763–1775. doi: 10.1016/j.jaip.2022.04.036. Epub 2022 May 10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.04.036</ArticleId><ArticleId IdType="pmc">PMC10038757</ArticleId><ArticleId IdType="pubmed">35561968</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol (1996) 14:619–48. doi: 10.1146/annurev.immunol.14.1.619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.14.1.619</ArticleId><ArticleId IdType="pubmed">8717527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol (2004) 34:1673–9. doi: 10.1002/eji.200425089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200425089</ArticleId><ArticleId IdType="pubmed">15162437</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajagopalan S, Long EO. KIR2DL4 (CD158d): An activation receptor for HLA-G. Front Immunol (2012) 20:3:258. doi: 10.3389/fimmu.2012.00258. eCollection 2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00258</ArticleId><ArticleId IdType="pmc">PMC3422731</ArticleId><ArticleId IdType="pubmed">22934097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, et al. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res (2021) 9:156–169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-20-0315</ArticleId><ArticleId IdType="pmc">PMC8284010</ArticleId><ArticleId IdType="pubmed">33229411</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Zhang W, Zhang JJ, He J, Zhu FM. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19). HLA (2020) 96: 194–6. doi: 10.1111/tan.13941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.13941</ArticleId><ArticleId IdType="pmc">PMC7276866</ArticleId><ArticleId IdType="pubmed">32424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Farias TDJ, Brugiapaglia S, Croci S, Magistroni P, Curcio C, Zguro K, et al. HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19. HLA (2024) 103: e15251. doi: 10.1111/tan.15251. Epub 2023 Oct 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.15251</ArticleId><ArticleId IdType="pmc">PMC10873037</ArticleId><ArticleId IdType="pubmed">37850268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal E, Gimeno L, Alcaraz MJ, Quadeer AA, Moreno M, Martínez-Sánchez MV, et al. Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019. J Infect Dis (2021) 224:229–240. doi: 10.1093/infdis/jiab228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab228</ArticleId><ArticleId IdType="pmc">PMC8135764</ArticleId><ArticleId IdType="pubmed">33928374</ArticleId></ArticleIdList></Reference><Reference><Citation>Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance (2020) 4: e202000955. doi: 10.26508/lsa.202000955. Print 2021 Feb.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202000955</ArticleId><ArticleId IdType="pmc">PMC7768198</ArticleId><ArticleId IdType="pubmed">33361110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao S, He Y, Kichula KM, Wang J, He J, Norman PJ, et al. High-Resolution Analysis Identifies High Frequency of KIR-A Haplotypes and Inhibitory Interactions of KIR With HLA Class I in Zhejiang Han. Front Immunol (2021) 12: 640334. doi: 10.3389/fimmu.2021.640334. eCollection 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.640334</ArticleId><ArticleId IdType="pmc">PMC8121542</ArticleId><ArticleId IdType="pubmed">33995358</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E, et al. Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing. American journal of human genetics (2016) 99: 375–91. doi: 10.1016/j.ajhg.2016.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.06.023</ArticleId><ArticleId IdType="pmc">PMC4974113</ArticleId><ArticleId IdType="pubmed">27486779</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao S, Kichula KM, Harrison GF, Farias TDJ, Palmer WH, Leaton LA, et al. The combinatorial diversity of KIR and HLA class I allotypes in Peninsular Malaysia. Immunology (2021) 162: 389–404. doi: 10.1111/imm.13289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13289</ArticleId><ArticleId IdType="pmc">PMC7968402</ArticleId><ArticleId IdType="pubmed">33283280</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin WM, Dandekar R, Augusto DG, Yusufali T, Heyn B, Hofmann J, et al. High-throughput Interpretation of Killer-cell Immunoglobulin-like Receptor Short-read Sequencing Data with PING. PLoS Comput Biol (2021) 17: e1008904. doi: 10.1371/journal.pcbi.1008904. eCollection 2021 Aug.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1008904</ArticleId><ArticleId IdType="pmc">PMC8360517</ArticleId><ArticleId IdType="pubmed">34339413</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Li J, Mao W, Zhang D, Liu M, Shan X, et al. HLA common and well-documented alleles in China. HLA (2018) 92: 199–205. doi: 10.1111/tan.13358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.13358</ArticleId><ArticleId IdType="pubmed">30073798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Galarza FF, McCabe A, Santos E, Jones J, Takeshita L, Ortega-Rivera ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res (2020) 48: D783–8. doi: 10.1093/nar/gkz1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1029</ArticleId><ArticleId IdType="pmc">PMC7145554</ArticleId><ArticleId IdType="pubmed">31722398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao S, Norman P, You X, Kichula KM, Dong L, Chen N, et al. High-resolution KIR and HLA genotyping in three Chinese ethnic minorities reveals distinct origins. HLA (2024) 103: e15482. doi: 10.1111/tan.15482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.15482</ArticleId><ArticleId IdType="pmc">PMC11027949</ArticleId><ArticleId IdType="pubmed">38625090</ArticleId></ArticleIdList></Reference><Reference><Citation>Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour (2010) 10: 564–7. doi: 10.1111/j.1755-0998.2010.02847.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-0998.2010.02847.x</ArticleId><ArticleId IdType="pubmed">21565059</ArticleId></ArticleIdList></Reference><Reference><Citation>Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute Respiratory Syndrome Coronavirus2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatrics (2020) 174: 882.</Citation><ArticleIdList><ArticleId IdType="pubmed">32320004</ArticleId></ArticleIdList></Reference><Reference><Citation>Salata C, Calistri A, Parolin C, Palù G. Coronaviruses: a paradigm of new emerging zoonotic diseases. Pathogens and Disease (2020) 77: ftaa006. doi: 10.1093/femspd/ftaa006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femspd/ftaa006</ArticleId><ArticleId IdType="pmc">PMC7108526</ArticleId><ArticleId IdType="pubmed">32065221</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu H, Du H, Li J, Wang Y, Wu X, Wang C, et al. Early prediction and identification for severe patients during the pandemic of COVID-19: a severe COVID-19 risk model constructed by multivariate logistic regression analysis. J Glob Health (2020) 10: 020510. doi: 10.7189/jogh.10.020510.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.10.020510</ArticleId><ArticleId IdType="pmc">PMC7567445</ArticleId><ArticleId IdType="pubmed">33110593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis (2020) 71: 1393–9. doi: 10.1093/cid/ciaa414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa414</ArticleId><ArticleId IdType="pmc">PMC7184473</ArticleId><ArticleId IdType="pubmed">32271369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I, Falfán-Valencia R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review. Front Immunol (2021) 12: 622176. doi: 10.3389/fimmu.2021.622176. eCollection 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622176</ArticleId><ArticleId IdType="pmc">PMC8047200</ArticleId><ArticleId IdType="pubmed">33868239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature (2020) 587: 610–2. doi: 10.1038/s41586-020-2818-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2818-3</ArticleId><ArticleId IdType="pubmed">32998156</ArticleId></ArticleIdList></Reference><Reference><Citation>Augusto DG, Murdolo LD, Chatzileontiadou DSM, Sabatino JJ Jr, Yusufali T, Peyser ND, et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature (2023) 620:128–136. doi: 10.1038/s41586-023-06331-x. Epub 2023 Jul 19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06331-x</ArticleId><ArticleId IdType="pmc">PMC10396966</ArticleId><ArticleId IdType="pubmed">37468623</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretta L, Moretta A. Unravelling natural killer cell function_ triggering and inhibitory human NK receptors. The EMBO Journal (2004) 233: 255–9. doi: 10.1038/sj.emboj.7600019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600019</ArticleId><ArticleId IdType="pmc">PMC1271745</ArticleId><ArticleId IdType="pubmed">14685277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet (2006) 7: 277–300. doi: 10.1146/annurev.genom.7.080505.115726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genom.7.080505.115726</ArticleId><ArticleId IdType="pubmed">16824023</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomar S, Alkhuriji A, Alkhulaifi FM, Mansour L, Al-Jurayyan A, Aldossari GS, et al. Relationship between KIR genotypes and HLA-ligands with SARS-CoV-2 infection in the Saudi population. J King Saud Univ Sci (2023) 35: 102416. doi: 10.1016/j.jksus.2022.102416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jksus.2022.102416</ArticleId><ArticleId IdType="pmc">PMC9622466</ArticleId><ArticleId IdType="pubmed">36338940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligotti ME, Aiello A, Accardi G, Calabrò A, Ciaccio M, Colomba C, et al. Distribution of KIR Genes and Their HLA Ligands in Different Viral Infectious Diseases: Frequency Study in Sicilian Population. Int J Mol Sci (2022) 23: 15466. doi: 10.3390/ijms232415466.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232415466</ArticleId><ArticleId IdType="pmc">PMC9779783</ArticleId><ArticleId IdType="pubmed">36555106</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruthamuthu S, Rajalingam K, Kaur N, Morvan MG, Soto J, Lee N, et al. Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19. Front Genet (2022) 13: 845474. doi: 10.3389/fgene.2022.845474. eCollection 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.845474</ArticleId><ArticleId IdType="pmc">PMC8902362</ArticleId><ArticleId IdType="pubmed">35273641</ArticleId></ArticleIdList></Reference><Reference><Citation>Langton DJ, Bourke SC, Lie BA, Reiff G, Natu S, Darlay R, et al. The influence of HLA genotype on the severity of COVID-19 infection. HLA (2021) 98:14–22. doi: 10.1111/tan.14284. Epub 2021 May 4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14284</ArticleId><ArticleId IdType="pmc">PMC8251294</ArticleId><ArticleId IdType="pubmed">33896121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajeer A, Jawdat D, Massadeh S, Aljawini N, Abedalthagafi MS, Arabi YM, et al. Association of KIR gene polymorphisms with COVID-19 disease. Clin Immunol (2022) 234: 108911. doi: 10.1016/j.clim.2021.108911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108911</ArticleId><ArticleId IdType="pmc">PMC8683215</ArticleId><ArticleId IdType="pubmed">34929414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousnina A, M’zah N, Hannachi N, Chelli M, Ben Ismaïl M. Echographic aspects of infectious endocarditis. Tunis Med (1986) 64:121–5. PMID: 3739022</Citation><ArticleIdList><ArticleId IdType="pubmed">3739022</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaton LA, Shortt J, Kichula KM, Tao S, Nemat-Gorgani N, Mentzer AJ, et al. Conservation, Extensive Heterozygosity, and Convergence of Signaling Potential All Indicate a Critical Role for KIR3DL3 in Higher Primates. Front Immunol (2019) 10: 24. doi: 10.3389/fimmu.2019.00024. eCollection 2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00024</ArticleId><ArticleId IdType="pmc">PMC6360152</ArticleId><ArticleId IdType="pubmed">30745901</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco R, Faria TC, Mine KL, Cristelli M, Medina-Pestana JO, Tedesco-Silva H, et al. HLA-A homozygosis is associated with susceptibility to COVID-19. HLA (2021) 98:122–131. DOI: 10.1111/tan.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.143</ArticleId><ArticleId IdType="pmc">PMC8446943</ArticleId><ArticleId IdType="pubmed">34165257</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir HRG, Majzoobi MM, Ebrahimi S, Noroozbeygi M, Hashemi SH, Keramat F, et al. Susceptibility and Severity of COVID-19 Are Both Associated With Lower Overall Viral-Peptide Binding Repertoire of HLA Class I Molecules, Especially in Younger People. Front Immunol (2022) 13:891816. DOI: 10.3389/fimmu.2022.891816</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.891816</ArticleId><ArticleId IdType="pmc">PMC9331187</ArticleId><ArticleId IdType="pubmed">35911710</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell. Cell Discov (2020) 6: 31. doi: 10.1038/s41421-020-0168-9. eCollection 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0168-9</ArticleId><ArticleId IdType="pmc">PMC7197635</ArticleId><ArticleId IdType="pubmed">32377375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martínez-Colón GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med (2020) 26: 1070–6. doi: 10.1038/s41591-020-0944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba A, Haider H, Sato T. Population Difference in Allele Frequency of HLA-C*05 and Its Correlation with COVID-19 Mortality. Viruses (2020) 12: 1333. doi: 10.3390/v12111333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12111333</ArticleId><ArticleId IdType="pmc">PMC7699862</ArticleId><ArticleId IdType="pubmed">33233780</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim MJW, Rajagopalan S, Altmann DM, Boyton RJ, Sun PD, Long EO. Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. Proc Natl Acad Sci USA (2019) 116:12964–12973. doi: 10.1073/pnas.1903781116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1903781116</ArticleId><ArticleId IdType="pmc">PMC6601252</ArticleId><ArticleId IdType="pubmed">31138701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch A, Nolan D, Furrer H, McKinnon E, John M, Mallal S, et al. HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin Infect Dis (2008) 46: 1921–5. doi: 10.1086/588479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/588479</ArticleId><ArticleId IdType="pubmed">18466093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>